Khlebnikova A, Kirshina A, Zakharova N, Ivanov R, Reshetnikov V
Int J Mol Sci. 2024; 25(23).
PMID: 39684849
PMC: 11642352.
DOI: 10.3390/ijms252313139.
Finger E, Coimbra T, Dastoli A
Einstein (Sao Paulo). 2024; 22:eAO0839.
PMID: 39661861
PMC: 11634341.
DOI: 10.31744/einstein_journal/2024AO0839.
Snik M, Stouthamer N, Hovius J, van Gool M
Eur J Immunol. 2024; 54(12):e2451063.
PMID: 39396370
PMC: 11628917.
DOI: 10.1002/eji.202451063.
Pfeifle A, Zhang W, Cao J, Thulasi Raman S, Anderson-Duvall R, Tamming L
Emerg Microbes Infect. 2024; 13(1):2399949.
PMID: 39221484
PMC: 11486199.
DOI: 10.1080/22221751.2024.2399949.
Steere A
J Infect Dis. 2024; 230(Supplement_1):S1-S10.
PMID: 39140724
PMC: 11322885.
DOI: 10.1093/infdis/jiae126.
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year.
Gingerich M, Nair N, Azevedo J, Samanta K, Kundu S, He B
NPJ Vaccines. 2024; 9(1):33.
PMID: 38360853
PMC: 10869809.
DOI: 10.1038/s41541-023-00802-y.
The Development of a Rabies Virus-Vectored Vaccine against , Targeting BBI39.
Rios S, Bhattachan B, Vavilikolanu K, Kitsou C, Pal U, Schnell M
Vaccines (Basel). 2024; 12(1).
PMID: 38250891
PMC: 10820992.
DOI: 10.3390/vaccines12010078.
Development of an mRNA-lipid nanoparticle vaccine against Lyme disease.
Pine M, Arora G, Hart T, Bettini E, Gaudette B, Muramatsu H
Mol Ther. 2023; 31(9):2702-2714.
PMID: 37533256
PMC: 10492027.
DOI: 10.1016/j.ymthe.2023.07.022.
The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer.
Gouttefangeas C, Klein R, Maia A
Front Immunol. 2023; 14:1212546.
PMID: 37409132
PMC: 10319254.
DOI: 10.3389/fimmu.2023.1212546.
Visiting Molecular Mimicry Once More: Pathogenicity, Virulence, and Autoimmunity.
Martins Y, Jurberg A, Daniel-Ribeiro C
Microorganisms. 2023; 11(6).
PMID: 37374974
PMC: 10301193.
DOI: 10.3390/microorganisms11061472.
Lyme disease and the pursuit of a clinical cure.
Adkison H, Embers M
Front Med (Lausanne). 2023; 10:1183344.
PMID: 37293310
PMC: 10244525.
DOI: 10.3389/fmed.2023.1183344.
Transmission Cycle of Tick-Borne Infections and Co-Infections, Animal Models and Diseases.
Rocha S, Velasquez C, Aquib A, Al-Nazal A, Parveen N
Pathogens. 2022; 11(11).
PMID: 36365060
PMC: 9696261.
DOI: 10.3390/pathogens11111309.
Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights.
Chen W, Strych U, Bottazzi M, Lin Y
Expert Rev Vaccines. 2022; 21(10):1405-1417.
PMID: 35836340
PMC: 9529901.
DOI: 10.1080/14760584.2022.2102484.
Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence.
Jafarzadeh A, Nemati M, Jafarzadeh S, Nozari P, Mortazavi S
J Endocrinol Invest. 2022; 45(10):1835-1863.
PMID: 35347651
PMC: 8960081.
DOI: 10.1007/s40618-022-01786-7.
The year that shaped the outcome of the OspA vaccine for human Lyme disease.
Dattwyler R, Gomes-Solecki M
NPJ Vaccines. 2022; 7(1):10.
PMID: 35087055
PMC: 8795424.
DOI: 10.1038/s41541-022-00429-5.
Recent Progress in Lyme Disease and Remaining Challenges.
Bobe J, Jutras B, Horn E, Embers M, Bailey A, Moritz R
Front Med (Lausanne). 2021; 8:666554.
PMID: 34485323
PMC: 8416313.
DOI: 10.3389/fmed.2021.666554.
Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?.
Sponaas A, Waage A, Vandsemb E, Misund K, Borset M, Sundan A
Front Immunol. 2021; 12:636375.
PMID: 33679794
PMC: 7928324.
DOI: 10.3389/fimmu.2021.636375.
Lyme Disease in Humans.
Radolf J, Strle K, Lemieux J, Strle F
Curr Issues Mol Biol. 2020; 42:333-384.
PMID: 33303701
PMC: 7946767.
DOI: 10.21775/cimb.042.333.
Immune Response to : Lessons from Lyme Disease Spirochetes.
Bockenstedt L, Wooten R, Baumgarth N
Curr Issues Mol Biol. 2020; 42:145-190.
PMID: 33289684
PMC: 10842262.
DOI: 10.21775/cimb.042.145.
Human and Veterinary Vaccines for Lyme Disease.
OBier N, Hatke A, Camire A, Marconi R
Curr Issues Mol Biol. 2020; 42:191-222.
PMID: 33289681
PMC: 7946718.
DOI: 10.21775/cimb.042.191.